PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
NCT06602271
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate the analgesic activity of PF614 (an oral oxycodone prodrug extended-release analgesic) for control of postsurgical pain in subjects scheduled for abdominoplasty surgery. The main question to be answered is: • To assess the analgesic efficacy of PF614 compared to placebo in subjects with moderate to severe pain following abdominoplasty. Participants will be asked to take oral blinded doses of study medication at about one hour before surgery starts, and then every 12 hours after surgery for up to 4 days.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Postoperative Pain, Acute
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Ensysce Biosciences
- Last updated on ClinicalTrials.gov
- January 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 1
- CenExel / Atlanta Center for Medical Research (ACMR) · Atlanta, GA
Texas · 1
- HD Research - Memorial Hermann Surgery Center · Houston, TX
Utah · 1
- CenExel / JBR · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.